Metastases-directed therapy in addition to standard systemic therapy in oligometastatic castration-resistant prostate cancer in Canada (GROUQ-PCS 9): a multicentre, open-label, randomised, phase 2 trial - 02/09/25
, Fred Saad, ProfMD b, Steven Tisseverasinghe, MD c, Rashmi Koul, MD d, Isabelle Thibault, MD e, Peter W M Chung, MD f, George Wakil, MD g, Michael Lock, MD h, Guila Delouya, MD b, Boris Bahoric, MD a, Andrew Feifer, MD i, Venkata Ramana Agnihotram, MD j, l, Theodoros Tsakiridis, MD k, Fabio L Cury, MD l, Rafika Dahmane, MD m, Nikhilesh Gajanan Patil, MD n, Scott Tyldesley, MD oSummary |
Background |
The role of metastasis-directed therapy (MDT) in castration-resistant prostate cancer (CRPC) remains unclear. Prostate Cancer Study 9 (PCS-9) aimed to evaluate the benefits of stereotactic body radiotherapy (SBRT) in addition to standard systemic therapy in patients with oligometastatic CRPC.
Methods |
This open-label, randomised, phase 2 trial was conducted across 13 Canadian academic and community oncology centres. Male patients aged 18 years or older, with an Eastern Cooperative Oncology Group performance status of 0–2, and histologically confirmed oligometastatic CRPC (≤5 metastases), who had progressed on androgen deprivation therapy (ADT), were randomly assigned (1:1) to ADT–enzalutamide (ENZA; 160 mg once daily) or ADT–ENZA–SBRT to all oligometastatic sites. Randomisation was completed by sequentially numbered, sealed opaque envelopes, and stratified by the location of the metastasis. The primary endpoint was radiographic progression-free survival. Analysis was performed on an intention-to-treat basis. This study is registered with ClinicalTrials.gov, NCT02685397, and was halted and completed at the phase 2 stage.
Findings |
Between Oct 18, 2016, and July 31, 2023, 102 male patients were randomly assigned to ADT–ENZA (n=49) or ADT–ENZA–SBRT (n=53); after excluding one patient per treatment group due to early withdrawal and insufficient data, 48 patients in the ADT–ENZA group and 52 patients in the ADT–ENZA–SBRT group were included in the final analysis. Most patients were White (80 [80%]) and median age was 73·0 years (IQR 67·0–79·5). At a median follow-up of 4·8 years (IQR 3·4–5·0), ADT–ENZA–SBRT significantly improved radiographic progression-free survival compared with ADT–ENZA alone (median radiographic progression-free survival, 4·6 years [95% CI 3·7–not reached] vs 2·3 years [1·4–3·7]; hazard ratio 0·48 [95% CI 0·27–0·86]; p=0·014). The most common grade 3 treatment related adverse event was impotence (eight [57%] of 14 patients in the ADT–ENZA group and nine [75%] of 12 patients in the ADT–ENZA–SBRT group). There were no grade 4 toxicities and no treatment-related deaths.
Interpretation |
These results demonstrate that SBRT, when combined with ADT–ENZA, prolongs disease control in oligometastatic CRPC by doubling median radiographic progression-free survival, with similar toxicity profiles between the groups. These findings support integrating SBRT into the treatment paradigm for oligometastatic CRPC.
Funding |
Jewish General Hospital (Astellas Canada).
Le texte complet de cet article est disponible en PDF.Plan
Vol 26 - N° 9
P. 1158-1167 - septembre 2025 Retour au numéro
Article précédent
- First-line benmelstobart plus anlotinib versus sunitinib in advanced renal cell carcinoma (ETER100): a multicentre, randomised, open-label, phase 3 trial
- Aiping Zhou, Pengfei Shen, Juan Li, Wang Qu, Zengjun Wang, Xiubao Ren, Yuan Li, Shusuan Jiang, Gang Li, Yu Zeng, Weijun Qin, Jin Wu, Peng Chen, Fangjian Zhou, Hongqian Guo, Zhigang Ji, Yongquan Wang, Zhisong He, Jitao Wu, Benkang Shi, Lian Liu, Xudong Yao, Lulin Ma, Ziling Liu, Xin Gou, Bin Fu, Shaogang Wang, Kui Jiang, Tie Chong, Xinhua Tu, Xu Zhang, Dexin Yu, Mulati Rexiati, Xueyi Xue, Jing Fei, Jianghou Wan, Liqun Jia, Yi He, Tongjian Cui, An-Qi Yang, Jun Guo, Xinan Sheng
- Prognostic and predictive value of baseline PSMA-PET total tumour volume and SUVmean in metastatic castration-resistant prostate cancer in ENZA-p (ANZUP1901): a substudy from a multicentre, open-label, randomised, phase 2 trial
- Louise Emmett, Nathan Papa, Shalini Subramaniam, Megan Crumbaker, Andrew Nguyen, Anthony M Joshua, Shahneen Sandhu, Andrew Weickhardt, Sze-Ting Lee, Siobhan Ng, Roslyn J Francis, Jeffrey C Goh, David A Pattison, Thean Hsiang Tan, Ian D Kirkwood, Narjess Ayati, Claire Niu, Michael S Hofman, Andrew James Martin, Hayley Thomas, Ian D Davis, Martin R Stockler, ENZA-p Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group, Louise Emmett, Nathan Papa, Shalini Subramaniam, Megan Crumbaker, Andrew Nguyen, Anthony M. Joshua, Shahneen Sandhu, Andrew Weickhardt, Sze-Ting Lee, Siobhan Ng, Roslyn J. Francis, Jeffrey C. Goh, David A. Pattison, Thean Hsiang Tan, Maddison Bills, Jasmine Brady, Ian D. Kirkwood, Narjess Ayati, Claire Niu, Michael S. Hofman, Andrew J. Martin, Hayley Thomas, Ian D. Davis, Martin R. Stockler, Nicole Tankard, Samantha Oakes, Alison Y Zhang, Jennifer Thompson, Thida Thein, Thomas Cusick, Shikha Sharma
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?